Why the study?
Targeting the molecular pathways underlying the cardiotoxicity associated with thoracic irradiation and doxorubicin could reduce treatment-associated morbidity and mortality.
Does anti-L1CAM antibody Ab417 prevent radiation- and doxorubicin-induced cardiotoxicity in preclinical models?
Population
Endothelial cells, whole-heart-irradiated mice, and cardiomyopathy patient-derived cardiovascular endothelial cells
Comparison
Anti-L1CAM antibody Ab417 treatment vs untreated or control conditions
Design
Preclinical laboratory and animal study
Authors
Loading...
Does not yet support practice change; leaves open L1CAM as a target to mitigate radiation- and doxorubicin-induced cardiotoxicity.
Does anti-L1CAM antibody Ab417 prevent radiation- and doxorubicin-induced cardiotoxicity in preclinical models?
Inhibiting nuclear L1CAM translocation with the Ab417 antibody reduces persistent DNA damage and prevents anticancer therapy-associated cardiotoxicity in preclinical models.
Nam et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: